Delaet Ingrid 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) Chief Regulatory Officer Ingrid Delaet Receives Award
What Happened
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences (NBIX), had multiple restricted stock units (RSUs) and performance RSUs (PRSUs) vest on Feb 12–13, 2026. The filing shows conversion/award transactions that resulted in the acquisition of a total of 61,008 shares (various "M" and "A" entries at $0.00) and the withholding of 13,126 shares to satisfy tax obligations ("F" entries). The withheld shares were valued at a combined $1,628,301 (withholdings priced at $123.10 and $124.12). No open‑market sale was reported — shares were withheld solely for taxes.
Key Details
- Transaction dates: Feb 12–13, 2026; filing date: Feb 17, 2026.
- Transaction codes: M = exercise/conversion of derivative; A = grant/award (vesting); F = shares withheld to satisfy tax withholding.
- Acquired (vested/converted): 61,008 shares (aggregate from multiple RSU/PRSU vesting/conversion lines, $0 exercise price).
- Shares withheld for taxes (disposed): 13,126 shares, totaling $1,628,301 (881 @ $123.10; remaining withholdings @ $124.12).
- Net increase in shares held (acquired minus withheld): 47,882 shares.
- Notable footnotes:
- F1: Shares were withheld by the company to satisfy tax withholding — no shares were sold on the open market.
- F2: PRSUs granted May 19, 2023 vested at 125% of target after certification on Feb 13, 2026, driving a large payout.
- F4–F6: Several RSU grants had scheduled vesting on Feb 12–13, 2026 (1,600; 1,401; 1,359 shares respectively).
- Shares owned after the transactions are not listed in the provided filing excerpt.
- Timeliness: Filing was submitted Feb 17 for Feb 12–13 transactions — this is beyond the typical 2-business-day Section 16 reporting window and may be late.
Context
These entries reflect routine equity compensation vesting and tax-withholding (not open-market selling). For derivative-related entries, the filing shows conversion/vesting of RSUs/PRSUs (M/A) and the company withholding shares (F) to cover tax liabilities — effectively a cashless/tax-satisfying action, not a market sell that signals liquidity or investment intent.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-02-12+1,600→ 6,656 total - Tax Payment
Common Stock
[F1]2026-02-12$123.10/sh−881$108,451→ 5,775 total - Exercise/Conversion
Common Stock
2026-02-13+1,401→ 7,176 total - Tax Payment
Common Stock
[F1]2026-02-13$124.12/sh−756$93,835→ 6,420 total - Exercise/Conversion
Common Stock
2026-02-13+1,359→ 7,779 total - Tax Payment
Common Stock
[F1]2026-02-13$124.12/sh−734$91,104→ 7,045 total - Award
Common Stock
[F2]2026-02-13+19,935→ 26,980 total - Tax Payment
Common Stock
[F1]2026-02-13$124.12/sh−10,755$1,334,911→ 16,225 total - Exercise/Conversion
Restricted Stock Unit
[F3][F4]2026-02-12−1,600→ 4,801 total→ Common Stock (1,600 underlying) - Exercise/Conversion
Restricted Stock Unit
[F3][F5]2026-02-13−1,401→ 2,802 total→ Common Stock (1,401 underlying) - Exercise/Conversion
Restricted Stock Unit
[F3][F6]2026-02-13−1,359→ 1,359 total→ Common Stock (1,359 underlying) - Award
Stock Option
[F7]2026-02-13+31,234→ 31,234 totalExercise: $124.12Exp: 2036-02-13→ Common Stock (31,234 underlying) - Award
Restricted Stock Unit
[F3][F8]2026-02-13+5,479→ 5,479 total→ Common Stock (5,479 underlying)
Footnotes (8)
- [F1]Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- [F2]On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F4]This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.
- [F5]This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award.
- [F6]This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award.
- [F7]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F8]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.